This is one in an occasional series highlighting the stories of patients who have received gene therapy for hemophilia B.
Gene therapy is now available for the treatment of hemophilia B in multiple countries, making appropriate adults eligible for this innovative treatment. CSL is proud to share stories of individuals who have received gene therapy, showcasing the real-world impact of this medical advancement.
Read a patient story from The Harvard Gazette
Additionally, CSL released data that assessed hemophilia B patients receiving a gene therapy in their fourth year following treatment.
As more gene therapy treatments are developed and approved, experts recommend shared decision making as a framework for patients working with their doctors to consider complex medical decisions.
